Utility of intravoxel incoherent motion magnetic resonance imaging and arterial spin labeling for recurrent glioma after bevacizumab treatment

Abstract

Background

Detecting recurrence of glioma on magnetic resonance imaging (MRI) is getting more and more important, especially after administration of new anti-tumor agent. However, it is still hard to identify.

Purpose

To examine the utility of intravoxel incoherent motion (IVIM) MRI and arterial spin labeling-cerebral blood flow (ASL-CBF) for recurrent glioma after initiation of bevacizumab (BEV) treatment.

Material and Methods

Thirteen patients (7 men, 6 women; age range = 41–82 years) with glioma (high grade, n = 11; low grade, n = 2) were enrolled in the study. IVIM parameters including apparent diffusion coefficient (ADC), true diffusion coefficient (D), and perfusion fraction (f) were obtained with 14 different b-values. We identified tumor progression during BEV therapy by MRI monitoring consisting of diffusion-weighted imaging (DWI), fluid-attenuated inversion recovery (FLAIR) imaging, and contrast-enhanced T1-weighted (CE-T1W) imaging by measuring tumor area. We also measured each parameter of IVIM and ASL-CBF, and calculated relative ADC (rADC), relative D (rD), relative f (rf), and relative CBF (rCBF) by obtaining the ratio between each area and the contralateral cerebral white matter. We calculated the rate of change (Δ) by subtracting values from those from the preceding MRI study, and obtained Spearman’s rank correlation coefficient (rs).

Results

Tumor progression was identified in nine patients (high grade, n = 7; low grade, n = 2). Negative correlations were identified between ΔrD and ΔDWI area (rs = –0.583), and between ΔrD and ΔCE-T1W imaging area (rs = –0.605).

Conclusion

Tumor progression after BEV treatment can be identified by decreasing rD.

Keywords

Intravoxel incoherent motion arterial spin labeling recurrent glioma bevacizumab

Get full access to this article

View all access options for this article.

References

Quinn

Jiang

Reardon

et al.

Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. J Neurooncol 2009; 95: 393–400.

Hicklin

Ellis

. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011–1027.

Huang

Held-Feindt

Buhl

et al.

Expression of VEGF and its receptors in different brain tumors. Neurol Res 2005; 27: 371–377.

Masi

Becchetti

Restano-Cassulini

et al.

hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines. Br J Cancer 2005; 93: 781–792.

Kreisl

Kim

Moore

et al.

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27: 740–745.

Friedman

Prados

Wen

et al.

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27: 4733–4740.

Batchelor

Sorensen

di Tomaso

et al.

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11: 83–95.

Pope

Lai

Nghiemphu

et al.

MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 2006; 66: 1258–1260.

Fatterpekar

Galheigo

Narayana

et al.

Treatment-related change versus tumor recurrence in high-grade gliomas: a diagnostic conundrum–use of dynamic susceptibility contrast-enhanced (DSC) perfusion MRI. Am J Roentgenol 2012; 198: 19–26.

10.

Federau

Meuli

O’Brien

et al.

Perfusion measurement in brain gliomas with intravoxel incoherent motion MRI. Am J Neuroradiol 2014; 35: 256–262.

11.

Y-C

Yan

L-F

et al.

Intravoxel incoherent motion diffusion-weighted MR imaging of gliomas: efficacy in preoperative grading. Sci Rep 2014; 4: 7208–7208.

12.

Suh

Kim

Lee

et al.

Atypical imaging features of primary central nervous system lymphoma that mimics glioblastoma: utility of intravoxel incoherent motion MR imaging. Radiology 2014; 272: 504–513.

13.

Kim

Suh

Kim

et al.

Histogram analysis of intravoxel incoherent motion for differentiating recurrent tumor from treatment effect in patients with glioblastoma: initial clinical experience. Am J Neuroradiol 2014; 35: 490–497.

14.

Khashbat Md

Abe Md

Ganbold Md

et al.

Correlation of 3D arterial spin labeling and multi-parametric dynamic susceptibility contrast perfusion MRI in brain tumors. J Med Invest 2016; 63: 175–181.

15.

Yoo

R-E

Choi

Cho

et al.

Tumor blood flow from arterial spin labeling perfusion MRI: a key parameter in distinguishing high-grade gliomas from primary cerebral lymphomas, and in predicting genetic biomarkers in high-grade gliomas. J Magn Reson Imaging 2013; 38: 852–860.

16.

Wen

Macdonald

Reardon

et al.

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010; 28: 1963–1972.

17.

Nagane

Kobayashi

Tanaka

et al.

Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report. Int J Clin Oncol 2014; 19: 16–23.

18.

Schmainda

Prah

Connelly

et al.

Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. Neuro Oncol 2014; 16: 880–888.

19.

Beppu

Terasaki

Sasaki

et al.

MRI and 11C-methyl-L-methionine PET differentiate bevacizumab true responders after initiating therapy for recurrent glioblastoma. Clin Nucl Med 2016; 41: 852–857.

20.

Colavolpe

Chinot

Metellus

et al.

FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan. Neuro Oncol 2012; 14: 649–657.

21.

Le Bihan

Breton

Lallemand

et al.

MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology 1986; 161: 401–407.

22.

Le Bihan

Breton

Lallemand

et al.

Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 1988; 168: 497–505.

23.

Yamada

Aung

Himeno

et al.

Diffusion coefficients in abdominal organs and hepatic lesions: evaluation with intravoxel incoherent motion echo-planar MR imaging. Radiology 1999; 210: 617–623.

24.

Mong

Ellingson

Nghiemphu

et al.

Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls. Am J Neuroradiol 2012; 33: 1763–1770.